FGFR2 and breast cancer: In preclinical studies, dovitinib showed the ability to inhibit FGFR1‐ and FGFR2‐amplified, but not FGFR‐normal breast cancer cell lines in vitro and inhibit tumour growth in FGFR1‐amplified breast cancer in vivo.150